Skip to main content

Table 3 Characteristics of hospitalizations in patients under biologic therapy compared to biologic-naïve patients

From: Biologic therapy is associated with a mild decrease in the rate of hospitalizations in pediatric IBD

Characteristic

Hospitalizations of patients under biologic therapy

n = 56

Hospitalizations of patients naïve to biologic therapy

n = 162

p

Age (year)

15.4 (12.2–17.2)

14.8 (11.3–16.4)

0.124

Males, n

29 (47.9%)

73 (45.1%)

0.385

Crohn’s disease

31 (55.4%)

116 (71.6%)

0.025

Ulcerative colitis

25 (44.6%)

46 (28.4%)

 

Duration from IBD diagnosis (year)

3.15 (1.14–4.13)

2 (0.5–4.15)

0.070

Indication of hospitalization:

  

0.945

IBD exacerbation

50 (89.3%)

144 (88.9%)

 

Therapy-related adverse events

6 (10.7%)

18 (11.1%)

 

Therapy at admission

 5-ASA

24 (42.9%)

94 (58%)

0.049

 Corticosteroids

9 (16.1%)

37 (22.8%)

0.285

 Enteral nutrition

14 (25%)

30 (18.5%)

0.297

 Methotrexate

2 (3.6%)

3 (1.9%)

0.459

 Azathioprine

14 (25%)

68 (42%)

0.024

Disease activity at admission

  

0.755

 Remission

3 (5.3%)

4 (2.5%)

 

 Mild

23 (41.1%)

69 (42.6%)

 

 Moderate

23 (41.1%)

66 (40.7%)

 

 Severe

7 (12.5%)

23 (14.2%)

 

Length of hospitalization

5 (2.75–7)

4 (2–7)

0.136

Blood cultures

32 (57.1%)

70 (43.2%)

0.072

Stool culture

19 (33.9%)

41 (25.3%)

0.213

Imaging studies

35 (62.5%)

113 (69.8%)

0.316

 US

16 (28.6%)

66 (40.1%)

0.105

 CT

5 (8.9%)

18 (11.1%)

0.647

 MRI

1 (1.8%)

2 (1.2%)

0.760

Endoscopy

 Upper GI endoscopy

3 (5.3%)

16 (9.9%)

0.301

 Lower GI endoscopy

6 (10.7%)

21 (13%)

0.660

Antibiotics

30 (53.6%)

79 (48.8%)

0.385

Blood transfusion

6 (10.7%)

8 (4.9%)

0.129

Surgery

3 (5.4%)

11 (6.8%)

0.706

 Abscess drainage

2 (3.6%)

8 (4.9%)

 

 Ileo-cecectomy

0

1 (0.6%)

 

 Others

1 (1.8%)

2 (1.2%)

 
  1. IBD inflammatory bowel disease, 5-ASA 5-aminosalicylic acid, US ultrasound, CT computed tomography, MRI magnetic resonance imaging, GI gastrointestinal